Author:
Mehra Ranee,Seiwert Tanguy Y.,Gupta Shilpa,Weiss Jared,Gluck Iris,Eder Joseph P.,Burtness Barbara,Tahara Makoto,Keam Bhumsuk,Kang Hyunseok,Muro Kei,Geva Ravit,Chung Hyun Cheol,Lin Chia-Chi,Aurora-Garg Deepti,Ray Archana,Pathiraja Kumudu,Cheng Jonathan,Chow Laura Q. M.,Haddad Robert
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
2. Pignon, J. P., le, M. A., Maillard, E. & Bourhis, J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother. Oncol. 92, 4–14 (2009).
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines (NCCN Guidelines®) in oncology: head and neck cancers. Version 1.2018.
https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
. Accessed 19 Apr 2018 (2018).
4. Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med 375, 1856–1867 (2016).
5. Chow, L. Q. et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J. Clin. Oncol. 34, 3838–3845 (2016).
Cited by
339 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献